HISERPIA
Clinical safety rating
cautionComprehensive clinical and safety monograph for HISERPIA (HISERPIA).
HISERPIA (risperidone) is an atypical antipsychotic that acts as a serotonin 5-HT2A and dopamine D2 receptor antagonist. It also binds to alpha1-adrenergic and histamine H1 receptors with high affinity, contributing to its therapeutic and side effect profile.
| Metabolism | Primarily metabolized by CYP2D6 and CYP3A4 to its major active metabolite, 9-hydroxyrisperidone (paliperidone). CYP2D6 poor metabolizers have higher risperidone levels. Minor pathways include N-dealkylation. |
| Excretion | Primarily renal (60-70% as unchanged drug) and biliary/fecal (20-30% as metabolites). |
| Half-life | Terminal elimination half-life is 12-15 hours; clinically, steady-state is reached after 2-3 days of regular dosing. |
| Protein binding | Approximately 90% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 1.5-2.5 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Oral: 80-95% due to extensive absorption with limited first-pass metabolism. |
| Onset of Action | Oral: 30-60 minutes; intravenous: 5-15 minutes. |
| Duration of Action | Oral: 6-12 hours; intravenous: 4-6 hours; duration may be prolonged in hepatic impairment. |
| Molecular Weight | 327.42 |
Initial: 0.25 mg orally twice daily; increase gradually to usual maintenance dose of 0.5–2 mg/day in divided doses. Maximum: 3 mg/day.
| Dosage form | TABLET |
| Renal impairment | No specific guidelines; use with caution in severe renal impairment (CrCl <30 mL/min) due to potential for accumulation. |
| Liver impairment | Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use. |
| Pediatric use | Not recommended for children under 12 years; limited data available. |
| Geriatric use | Start at 0.125 mg orally twice daily; increase slowly due to increased sensitivity and risk of hypotension. |
| 1st trimester | Contraindicated due to risk of teratogenicity and fetal malformations based on animal studies and limited human data. |
| 2nd trimester | Contraindicated; use only if maternal benefit outweighs potential fetal harm, with careful monitoring. |
| 3rd trimester | Contraindicated; may cause neonatal adverse effects such as withdrawal syndrome or respiratory depression. |
Clinical note
Comprehensive clinical and safety monograph for HISERPIA (HISERPIA).
| Placental transfer | Crosses placenta; detected in fetal plasma at 50-80% of maternal levels based on animal and human placental perfusion studies. |
| Breastfeeding | Excreted into breast milk in low amounts; however, due to potential for serious adverse reactions in nursing infants, discontinue nursing or the drug, considering importance to mother. |
| Lactation Rating | L4 (Possibly Hazardous - Avoid if Possible) |
| Teratogenic Risk | First trimester: Case reports of major congenital malformations including neural tube defects and cardiovascular anomalies, likely due to inhibition of folate metabolism. Second and third trimesters: Associated with oligohydramnios, fetal renal dysfunction, and skull ossification defects. Risk category X. |
| Fetal Monitoring | Maternal: CBC, LFTs, renal function, serum drug levels (if available), fetal surveillance: serial ultrasound for growth, amniotic fluid index, and fetal echocardiography. Consider nonstress test or biophysical profile in third trimester. |
| Fertility Effects | May impair spermatogenesis and oogenesis based on animal studies; human data limited. Reversible upon discontinuation. May disrupt menstrual cycle. |
■ FDA Black Box Warning
Increased risk of death in elderly patients with dementia-related psychosis. HISERPIA is not approved for this population.
| Serious Effects |
Hypersensitivity to active substance or excipientsPregnancyBreastfeedingSevere hepatic impairmentHistory of QT prolongation or concurrent use of QT-prolonging agents
| Precautions | Cerebrovascular adverse events (including stroke) in elderly dementia patients, Neuroleptic Malignant Syndrome (NMS), Tardive dyskinesia, Hyperglycemia and diabetes mellitus, Hyperprolactinemia, Orthostatic hypotension, Seizures, Leukopenia/neutropenia/agranulocytosis, Body temperature dysregulation, Dysphagia, Priapism |
| Food/Dietary | Avoid alcohol and tyramine-rich foods (aged cheese, cured meats, fermented products) as they may exacerbate hypertensive effects. Grapefruit juice may alter drug metabolism; limit intake. |
| Clinical Pearls | Hisergia is a combination of reserpine (0.1 mg) and dihydroergocristine (0.5 mg) used for hypertension. Monitor for bradycardia and orthostatic hypotension, especially in elderly. Reserpine depletes catecholamines; avoid in patients with depression or peptic ulcer. Dihydroergocristine is an ergot alkaloid; caution with CYP3A4 inhibitors due to risk of ergotism. Titrate slowly and check blood pressure and heart rate regularly. |
| Patient Advice | Take exactly as prescribed; do not skip doses or double up. · Rise slowly from sitting or lying to prevent dizziness. · Avoid driving or operating heavy machinery until you know how this medicine affects you. · Report any signs of depression, slow heartbeat, or fainting to your doctor. · Do not drink alcohol; it may worsen side effects. |
Loading safety data…